EIF2AK3 and colorectal carcinoma: Similar results have previously demonstrated that varying growth sensitivities to pharmacological inhibition of mitogen-activated protein kinase kinases (MEKs) do not correlate with pERK activity in KRAS and BRAF mutant CRC cell lines44,45.